Moffitt logo

COVID-19 Safety Precautions: Find the Latest Visitor and Mask Policies. Learn More

Clinical Trials Search

Clinical Trial 21129

Cancer Type: Multiple
Study Type: Treatment
NCT#: NCT04774952

Phase: Phase I
Prinicipal Investigator: Eric Haura

Call 813-745-6100
or 1-800-679-0775 Learn More
Overview

Study Title

A Phase 1/1b, Open-Label, Multicenter, Dose-Escalation Study of RMC-5552 Monotherapy in Adult Subjects with Relapsed/Refractory Solid Tumors

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of escalating doses of RMC-5552 monotherapy in adult participants with relapsed/refractory solid tumors and to identify the recommended Phase 2 dose (RP2D).

Objective

Primary To characterize the safety and tolerability of RMC-5552 monotherapy in subjects with relapsed/refractory solid tumors To define the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) for RMC-5552 monotherapy in subjects with relapsed/refractory solid tumors Secondary To characterize the plasma pharmacokinetics (PK) of RMC-5552 after single- and repeat-dose administration To evaluate the preliminary antitumor effects of RMC-5552 monotherapy in subjects with relapsed/refractory solid tumors harboring specific genotypic aberrations

Treatments

Therapies

Medications

RMC-5552 ()

Inclusion Criteria

  • Participants (male or female) >;18 years of age
  • Participants who have advanced solid tumors that have failed, are intolerant to, or are considered ineligible for standard of care anticancer treatments including approved drugs for oncogenic drivers in their tumor type
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
  • Participants in the Dose-Expansion Component must have molecular aberrations in the mTOR pathway
  • Adequate hematologic, hepatic and renal function

  • Exclusion Criteria

  • Known or suspected leptomeningeal or brain metastases or spinal cord compression
  • Primary central nervous system (CNS) tumors
  • Clinically significant cardiac disease
  • Active, clinically significant interstitial lung disease or pneumonitis
  • Subjects with abnormal fasting glucose, type 1 diabetes, or uncontrolled type 2 diabetes are excluded.
  • Subjects with stomatitis or mucositis of any grade

  • If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.

    ;